Focused On-demand Library for Pre-mRNA-processing factor 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O94906

UPID:

PRP6_HUMAN

Alternative names:

Androgen receptor N-terminal domain-transactivating protein 1; PRP6 homolog; U5 snRNP-associated 102 kDa protein

Alternative UPACC:

O94906; B2RAR5; B3KMC6; O95109; Q5VXS5; Q9H3Z1; Q9H4T9; Q9H4U8; Q9NTE6

Background:

Pre-mRNA-processing factor 6, also known as Androgen receptor N-terminal domain-transactivating protein 1, plays a crucial role in pre-mRNA splicing as part of the U4/U6-U5 tri-snRNP complex. This protein is essential for the assembly of the spliceosome, a complex responsible for removing introns from pre-mRNA. It also modulates the transactivation activity of AR and NR3C1, highlighting its significance in gene expression regulation.

Therapeutic significance:

Pre-mRNA-processing factor 6 is linked to Retinitis pigmentosa 60, a retinal dystrophy characterized by loss of vision and pigment deposits in the retina. Understanding the role of Pre-mRNA-processing factor 6 could open doors to potential therapeutic strategies for this debilitating condition.